{
    "xml": "<topic id=\"PHP6560\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/sodium-aurothiomalate\" basename=\"sodium-aurothiomalate\" title=\"SODIUM AUROTHIOMALATE\">\n<title>SODIUM AUROTHIOMALATE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1139\" namespace=\"/interactions/list-of-drug-interactions/sodium-aurothiomalate\">Sodium Aurothiomalate</xref>\n</p>\n<data name=\"vtmid\">68702006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_308759379\" title=\"Disease-modifying anti-rheumatic drugs\">Disease-modifying anti-rheumatic drugs</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP46510\" outputclass=\"indicationsAndDose\" rev=\"1.27\" parent=\"/drugs/sodium-aurothiomalate\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Active progressive rheumatoid arthritis (administered on expert advice)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Test dose 10&#8239;mg, followed by 50&#8239;mg once weekly until there is definite evidence of remission, then reduced to 50&#8239;mg every 4&#8239;weeks continued for up to 5 years after complete remission, dose to be reduced gradually. Benefit is not expected until 300&#8211;500&#8239;mg has been given; it should be discontinued if there is no remission after 1&#8239;g has been given.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Relapse in patients who have previously received sodium aurothiomalate therapy for active progressive rheumatoid arthritis (administered on expert advice)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>50&#8239;mg once weekly until control has been obtained again, then reduced to 50&#8239;mg every 4&#8239;weeks continued for up to 5 years after complete remission, if no response is seen within 2 months, alternative treatment should be sought.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46562\" outputclass=\"contraindications\" rev=\"1.10\" parent=\"/drugs/sodium-aurothiomalate\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Exfoliative dermatitis</ph>; <ph outputclass=\"contraindication\">history of blood disorders</ph>; <ph outputclass=\"contraindication\">history of bone marrow aplasia</ph>; <ph outputclass=\"contraindication\">necrotising enterocolitis</ph>; <ph outputclass=\"contraindication\">pulmonary fibrosis</ph>; <ph outputclass=\"contraindication\">systemic lupus erythematosus</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46580\" outputclass=\"cautions\" rev=\"1.13\" parent=\"/drugs/sodium-aurothiomalate\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Colitis</ph>; <ph outputclass=\"caution\">eczema</ph>; <ph outputclass=\"caution\">elderly</ph>; <ph outputclass=\"caution\">history of urticaria</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p>Sodium aurothiomalate should be discontinued in the presence of blood disorders, gastro-intestinal bleeding (associated with ulcerative enterocolitis), or unexplained proteinuria (associated with immune complex nephritis) which is repeatedly above 300&#8239;mg/litre.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46501\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/sodium-aurothiomalate\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (sodium aurothiomalate).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46472\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/sodium-aurothiomalate\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">blood disorders (sometimes sudden and fatal)</ph>; <ph outputclass=\"sideEffect\">colitis</ph>; <ph outputclass=\"sideEffect\">gold deposits in eye</ph>; <ph outputclass=\"sideEffect\">hepatotoxicity with cholestatic jaundice</ph>; <ph outputclass=\"sideEffect\">irreversible pigmentation in sun-exposed areas (on prolonged parenteral treatment)</ph>; <ph outputclass=\"sideEffect\">mouth ulcers</ph>; <ph outputclass=\"sideEffect\">nephrotic syndrome</ph>; <ph outputclass=\"sideEffect\">peripheral neuropathy</ph>; <ph outputclass=\"sideEffect\">proteinuria</ph>; <ph outputclass=\"sideEffect\">pulmonary fibrosis</ph>; <ph outputclass=\"sideEffect\">severe anaphylactic reactions</ph>; <ph outputclass=\"sideEffect\">skin reactions</ph>; <ph outputclass=\"sideEffect\">stomatitis</ph>; <ph outputclass=\"sideEffect\">taste disturbances</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>Rashes with pruritus often occur after 2 to 6 months of treatment and may necessitate discontinuation.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46494\" outputclass=\"pregnancy\" parent=\"/drugs/sodium-aurothiomalate\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Consider reducing dose and frequency.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid but limited data suggests usually not necessary to withdraw if condition well controlled.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46592\" outputclass=\"breastFeeding\" parent=\"/drugs/sodium-aurothiomalate\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;present in milk; theoretical possibility of rashes and idiosyncratic reactions.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46528\" outputclass=\"hepaticImpairment\" parent=\"/drugs/sodium-aurothiomalate\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Caution in mild to moderate impairment.</p>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46478\" outputclass=\"renalImpairment\" parent=\"/drugs/sodium-aurothiomalate\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Caution in mild to moderate impairment.</p>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46458\" outputclass=\"monitoringRequirements\" parent=\"/drugs/sodium-aurothiomalate\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Urine tests and full blood counts (including total and differential white cell and platelet counts) must be performed before starting treatment and before each intramuscular injection.</p>\n<p>Monitor for pulmonary fibrosis with annual chest X-ray.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46482\" outputclass=\"patientAndCarerAdvice\" rev=\"1.9\" parent=\"/drugs/sodium-aurothiomalate\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients should be advised to seek prompt medical attention if diarrhoea, sore throat, fever, infection, non-specific illness, unexplained bleeding and bruising, purpura, mouth ulcers, metallic taste, rash, breathlessness, or cough develop.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP6560-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/sodium-aurothiomalate\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76815\" title=\"Solution for injection\" namespace=\"/drugs/sodium-aurothiomalate/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78421\" namespace=\"/treatment-summaries/rheumatic-disease-suppressing-drugs\" title=\"Rheumatic disease, suppressing drugs\" count=\"1\" rel=\"backlink\">Rheumatic disease, suppressing drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1139\" namespace=\"/interactions/list-of-drug-interactions/sodium-aurothiomalate\" title=\"Sodium Aurothiomalate\" count=\"1\" rel=\"link\">Sodium Aurothiomalate</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76815\" namespace=\"/drugs/sodium-aurothiomalate/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP6560",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/sodium-aurothiomalate",
    "basename": "sodium-aurothiomalate",
    "title": "SODIUM AUROTHIOMALATE",
    "interactants": [
        {
            "id": "bnf_int_1139",
            "label": "Sodium Aurothiomalate"
        }
    ],
    "vtmid": "68702006",
    "drugClassification": [
        "Disease-modifying anti-rheumatic drugs"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Active progressive rheumatoid arthritis (administered on expert advice)",
                        "html": "Active progressive rheumatoid arthritis (administered on expert advice)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "Test dose 10 mg, followed by 50 mg once weekly until there is definite evidence of remission, then reduced to 50 mg every 4 weeks continued for up to 5 years after complete remission, dose to be reduced gradually. Benefit is not expected until 300&#8211;500 mg has been given; it should be discontinued if there is no remission after 1 g has been given.",
                        "html": "<p>Test dose 10&#8239;mg, followed by 50&#8239;mg once weekly until there is definite evidence of remission, then reduced to 50&#8239;mg every 4&#8239;weeks continued for up to 5 years after complete remission, dose to be reduced gradually. Benefit is not expected until 300&#8211;500&#8239;mg has been given; it should be discontinued if there is no remission after 1&#8239;g has been given.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Relapse in patients who have previously received sodium aurothiomalate therapy for active progressive rheumatoid arthritis (administered on expert advice)",
                        "html": "Relapse in patients who have previously received sodium aurothiomalate therapy for active progressive rheumatoid arthritis (administered on expert advice)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "50 mg once weekly until control has been obtained again, then reduced to 50 mg every 4 weeks continued for up to 5 years after complete remission, if no response is seen within 2 months, alternative treatment should be sought.",
                        "html": "<p>50&#8239;mg once weekly until control has been obtained again, then reduced to 50&#8239;mg every 4&#8239;weeks continued for up to 5 years after complete remission, if no response is seen within 2 months, alternative treatment should be sought.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Exfoliative dermatitis",
                "html": "Exfoliative dermatitis"
            },
            {
                "type": "contraindications",
                "textContent": "history of blood disorders",
                "html": "history of blood disorders"
            },
            {
                "type": "contraindications",
                "textContent": "history of bone marrow aplasia",
                "html": "history of bone marrow aplasia"
            },
            {
                "type": "contraindications",
                "textContent": "necrotising enterocolitis",
                "html": "necrotising enterocolitis"
            },
            {
                "type": "contraindications",
                "textContent": "pulmonary fibrosis",
                "html": "pulmonary fibrosis"
            },
            {
                "type": "contraindications",
                "textContent": "systemic lupus erythematosus",
                "html": "systemic lupus erythematosus"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Colitis",
                "html": "Colitis"
            },
            {
                "type": "cautions",
                "textContent": "eczema",
                "html": "eczema"
            },
            {
                "type": "cautions",
                "textContent": "elderly",
                "html": "elderly"
            },
            {
                "type": "cautions",
                "textContent": "history of urticaria",
                "html": "history of urticaria"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "Sodium aurothiomalate should be discontinued in the presence of blood disorders, gastro-intestinal bleeding (associated with ulcerative enterocolitis), or unexplained proteinuria (associated with immune complex nephritis) which is repeatedly above 300 mg/litre.",
                "html": "<p>Sodium aurothiomalate should be discontinued in the presence of blood disorders, gastro-intestinal bleeding (associated with ulcerative enterocolitis), or unexplained proteinuria (associated with immune complex nephritis) which is repeatedly above 300&#8239;mg/litre.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (sodium aurothiomalate).",
                "html": "<p>Appendix 1 (sodium aurothiomalate).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "blood disorders (sometimes sudden and fatal)",
                        "html": "blood disorders (sometimes sudden and fatal)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "colitis",
                        "html": "colitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "gold deposits in eye",
                        "html": "gold deposits in eye",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatotoxicity with cholestatic jaundice",
                        "html": "hepatotoxicity with cholestatic jaundice",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "irreversible pigmentation in sun-exposed areas (on prolonged parenteral treatment)",
                        "html": "irreversible pigmentation in sun-exposed areas (on prolonged parenteral treatment)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "mouth ulcers",
                        "html": "mouth ulcers",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nephrotic syndrome",
                        "html": "nephrotic syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "peripheral neuropathy",
                        "html": "peripheral neuropathy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "proteinuria",
                        "html": "proteinuria",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pulmonary fibrosis",
                        "html": "pulmonary fibrosis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "severe anaphylactic reactions",
                        "html": "severe anaphylactic reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "skin reactions",
                        "html": "skin reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "stomatitis",
                        "html": "stomatitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "taste disturbances",
                        "html": "taste disturbances",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "Rashes with pruritus often occur after 2 to 6 months of treatment and may necessitate discontinuation.",
                "html": "<p>Rashes with pruritus often occur after 2 to 6 months of treatment and may necessitate discontinuation.</p>"
            }
        ]
    },
    "pregnancy": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Consider reducing dose and frequency.",
                "html": "<p>Consider reducing dose and frequency.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid but limited data suggests usually not necessary to withdraw if condition well controlled.",
                "html": "<p>Manufacturer advises avoid but limited data suggests usually not necessary to withdraw if condition well controlled.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;present in milk; theoretical possibility of rashes and idiosyncratic reactions.",
                "html": "<p>Manufacturer advises avoid&#8212;present in milk; theoretical possibility of rashes and idiosyncratic reactions.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Caution in mild to moderate impairment.\n\nAvoid in severe impairment.",
                "html": "<p>Caution in mild to moderate impairment.</p><p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Caution in mild to moderate impairment.\n\nAvoid in severe impairment.",
                "html": "<p>Caution in mild to moderate impairment.</p><p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Urine tests and full blood counts (including total and differential white cell and platelet counts) must be performed before starting treatment and before each intramuscular injection.\n\nMonitor for pulmonary fibrosis with annual chest X-ray.",
                "html": "<p>Urine tests and full blood counts (including total and differential white cell and platelet counts) must be performed before starting treatment and before each intramuscular injection.</p><p>Monitor for pulmonary fibrosis with annual chest X-ray.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients should be advised to seek prompt medical attention if diarrhoea, sore throat, fever, infection, non-specific illness, unexplained bleeding and bruising, purpura, mouth ulcers, metallic taste, rash, breathlessness, or cough develop.",
                "html": "<p>Patients should be advised to seek prompt medical attention if diarrhoea, sore throat, fever, infection, non-specific illness, unexplained bleeding and bruising, purpura, mouth ulcers, metallic taste, rash, breathlessness, or cough develop.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76815",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78421",
                "label": "Rheumatic disease, suppressing drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1139",
                "label": "Sodium Aurothiomalate",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76815",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}